These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2867153)

  • 1. Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease.
    Thomas P; Richards D; Richards A; Rogers L; Evans BK; Dew MJ; Rhodes J
    J Pharm Pharmacol; 1985 Oct; 37(10):757-8. PubMed ID: 2867153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of prednisolone in patients with Crohn's disease.
    Shaffer JA; Williams SE; Turnberg LA; Houston JB; Rowland M
    Gut; 1983 Mar; 24(3):182-6. PubMed ID: 6826099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent.
    Rodrigues CA; Nabi EM; Spiliadis C; McIntyre PB; Phongsathorn V; Lennard-Jones JE; Rosen A; Willoughby JM
    Aliment Pharmacol Ther; 1987 Oct; 1(5):391-9. PubMed ID: 2979682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal absorption of ursodeoxycholic acid in children and adolescents with inflammatory bowel disease.
    Fujisawa T; Kimura A; Ushijima K; Nakashima E; Inoue T; Yamashita Y; Kato H
    J Pediatr Gastroenterol Nutr; 1998 Mar; 26(3):279-85. PubMed ID: 9523862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon.
    Ukabam SO; Clamp JR; Cooper BT
    Digestion; 1983; 27(2):70-4. PubMed ID: 6414866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of inflammatory bowel disease on absorption and disposition of prednisolone.
    Milsap RL; George DE; Szefler SJ; Murray KA; Lebenthal E; Jusko WJ
    Dig Dis Sci; 1983 Feb; 28(2):161-8. PubMed ID: 6825536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease.
    Trinchieri A; Lizzano R; Castelnuovo C; Zanetti G; Pisani E
    Arch Ital Urol Androl; 2002 Jun; 74(2):61-4. PubMed ID: 12161938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis.
    Silverstein E; Fierst SM; Simon MR; Weinstock JV; Friedland J
    Am J Clin Pathol; 1981 Feb; 75(2):175-8. PubMed ID: 6258421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acid studies in patients with Crohn's colitis.
    Rutgeerts P; Ghoos Y; Vantrappen G
    Gut; 1979 Dec; 20(12):1072-7. PubMed ID: 527881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease.
    Casellas F; Aguadé S; Soriano B; Accarino A; Molero J; Guarner L
    Am J Gastroenterol; 1986 Sep; 81(9):767-70. PubMed ID: 3529937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use.
    Ford GA; Oliver PS; Shepherd NA; Wilkinson SP
    Aliment Pharmacol Ther; 1992 Feb; 6(1):31-40. PubMed ID: 1543815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-absorption of enteric-coated prednisolone. Normal absorption of non-enteric-coated prednisolone in a patient with Crohn's disease and massive intestinal resection.
    Olivesi A
    Therapie; 1985; 40(1):5-7. PubMed ID: 4002184
    [No Abstract]   [Full Text] [Related]  

  • 14. Absorption studies in patients with Crohn's disease and in patients with ulcerative colitis.
    Andersson H; Dotevall G; Gillberg G; Jagenburg R; Kock NG
    Acta Med Scand; 1971 Nov; 190(5):407-10. PubMed ID: 5149268
    [No Abstract]   [Full Text] [Related]  

  • 15. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
    Fischer C; Klotz U
    Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
    [No Abstract]   [Full Text] [Related]  

  • 16. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.
    Daig R; Andus T; Aschenbrenner E; Falk W; Schölmerich J; Gross V
    Gut; 1996 Feb; 38(2):216-22. PubMed ID: 8801200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal radioiodide excretion following intravenous injection of 131-I-albumin and 125-I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis.
    Jarnum S; Jensen KB
    Gastroenterology; 1975 Jun; 68(6):1433-44. PubMed ID: 1132626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary gonadotrophin excretion in patients with ulcerative colitis and Crohn's disease treated with A.C.T.H. and corticosteroids.
    Crean GP; Loraine JA; Bell ET; Card WI; Sircus W
    Gut; 1966 Dec; 7(6):597-605. PubMed ID: 4289244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.